Temelimab is under clinical development by GeNeuro and currently in Phase II for Unspecified Central Nervous System Disorders. According to GlobalData, Phase II drugs for Unspecified Central Nervous System Disorders have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Temelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Temelimab overview

Temelimab (GnbAC-1) is under development for the treatment of secondary progressive multiple sclerosis and neuropsychiatric syndromes of Post-COVID . It is administered intravenously as a solution. The drug candidate targets pathogenic proteins (Env) of the multiple sclerosis retrovirus (MSRV). GNbAC-1 is a humanized monoclonal antibody of immunoglobulin G4 type. It was also under development for the treatment of relapsing-remitting multiple sclerosis and type I diabetes,  relapsing-remitting multiple sclerosis and chronic inflammatory demyelinating polyneuropathy (CIDP).

GeNeuro overview

GeNeuro is a clinical-stage biopharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. It provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develops therapeutic products for neurological disorders including multiple sclerosis, schizophrenia and other diseases of the nervous system. The company offers therapeutic monoclonal antibodies to neutralize the immunopathogenic multiple sclerosis associated RetroViral element envelope proteins detected in MS brain plaques. GeNeuro is headquartered in Geneva, Switzerland.

For a complete picture of Temelimab’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.